is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.
04.29.14 Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177
for the Treatment of Kidney Stones
01.15.14 Allena Pharmaceuticals to Present at the
2014 J.P. Morgan Healthcare Conference